U.S. markets closed

Atreca, Inc. (BCEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.29+0.18 (+2.95%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close6.11
Open6.14
Bid6.00 x 800
Ask6.36 x 1200
Day's Range6.03 - 6.43
52 Week Range4.80 - 20.29
Volume436,817
Avg. Volume1,062,792
Market Cap232.066M
Beta (5Y Monthly)0.04
PE Ratio (TTM)N/A
EPS (TTM)-2.71
Earnings DateNov 10, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Atreca, Inc.
    NKTR: What does Argus have to say about NKTR?NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $13.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Atreca to Present at Upcoming Virtual Investor Conferences

    SAN CARLOS, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming virtual investor conferences: HC Wainwright 23rd Annual Global Investment ConferenceSeptember 13-15, 2021Presentation available beginning September 13 Baird G

  • GlobeNewswire

    Atreca Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

    SAN CARLOS, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2021, and provided an overview of recent developments. “We recently announced initial summary data from the dose escalation portion of the Phase 1b tr

  • Simply Wall St.

    We're Not Very Worried About Atreca's (NASDAQ:BCEL) Cash Burn Rate

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...